Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database

Background: Mirabegron, the first β-3 adrenergic receptor agonist, received approval from the Food and Drug Administration (FDA) in 2012 for the treatment of overactive bladder (OAB). This pharmacovigilance study investigated the safety profile of mirabegron treatment using the US FDA Adverse Event...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Junwei Wang, Aiwei Zhang, Miaoyong Ye, Cunming Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Subjects:	mirabegron overactive bladder adverse event pharmacovigilance FAERS
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1376535/full